Replies to post #91690 on Biotech Values

[masterlongevity]

i think gammagard is a very dark horse.

the costs to manufacture are very high, drug pricing will be a concern.

also, by 2014, another 3 potential disease modifying drugs have a chance to get to market:

Bapineuzumab
Lilly's Gamma secretase inhibitor
Lilly antibody solaneuzumab


but in last 3 years: alzhemed and flurizan and now dimebon have failed ph 3